Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00627263 · ClinicalTrials.gov registry record · NA

Stress Reduction to Reduce Risk for Arrhythmia in ICD Patients (The RISTA Study)

A NA study, sponsored by Yale University.

Completed
Registry status
NA
Development phase
314
Enrollment target

NCT00627263: Completed NA study, sponsored by Yale University.

NCT00627263 is a NA study that has completed, run by Yale University. The registered enrollment target is 314 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00627263, a NA study, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
314 participants
Enrollment target

Study Summary

An implantable cardioverter defibrillator (ICD) is a small device that is implanted in the chest and uses electrical shocks to control arrhythmias, which are abnormal heart rhythms. Arrhythmias can be caused by many factors, including stress and anger. This study will evaluate the use of a stress reduction treatment (SRT) program aimed at reducing the occurrence of arrhythmias that require treatment with an ICD shock.

Primary Outcome

The occurrence of ICD shock treated ventricular arrhythmia

Interventions

  • BEHAVIORAL Stress reduction treatment (SRT) program

Trial Details

FieldValue
Enrollment Target 314 participants
Start Date 2008-01
Est. Completion 2012-12
Phase NA
Yale University

1,492 total trials

What the finished NCT00627263 record still lists

NCT00627263 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 1 intervention - of which Stress reduction treatment (SRT) program is the first listed.

NCT00627263 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00627263 about?

NCT00627263 is a clinical study titled "Stress Reduction to Reduce Risk for Arrhythmia in ICD Patients (The RISTA Study)". An implantable cardioverter defibrillator (ICD) is a small device that is implanted in the chest and uses electrical shocks to control arrhythmias, which are abnormal heart rhythms. Arrhythmias can be caused by many factors, including stress and anger. This study will evaluate the use of a stress re...

What is the current status of trial NCT00627263?

This trial is currently completed. It is a NA study. The enrollment target is 314 participants. The study started on 2008-01. Estimated completion is 2012-12.

What interventions are being tested in trial NCT00627263?

The interventions under investigation include: Stress reduction treatment (SRT) program (BEHAVIORAL).

Who is sponsoring clinical trial NCT00627263?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00627263's enrollment target sits among peer trials

314 323rd of 2000 higher than 1,678 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03866382 · 314 participants · Phase 2

    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • NCT04500756 · 314 participants · Phase 2

    Limiting AAA With Metformin (LIMIT) Trial

  • NCT06167746 · 314 participants · Phase 3

    iCare4Me Transitions

  • NCT06883097 · 314 participants · NA

    Quitting Matters Human Immunodeficiency Virus Hybrid Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00627263, the US trial registry maintained by the National Library of Medicine. NCT00627263 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.